Biological E gets drug regulator's approval to conduct phase 2/3 trials on children

Meanwhile, Zydus Cadila's needle-free COVID-19 vaccine ZyCoV-D has already received emergency use authorisation (EUA) to inoculate children in the age group of 12-18. It is expected to be administered from the first week of October.

migrator

Updated:2nd Sep, 2021 at 10:24 AM

New Delhi

The Drug Controller General of India (DCGI) on Wednesday granted permission to Hyderabad-based Biological E Limited to conduct Phase 2 & 3 clinical trials for its anti-COVID shots called Corbevax on children between 5 and 18 years of age with certain conditions, sources told ANI. The trial will be conducted in ten locations.

The permission has been given to Biological E after the recommendation from the Subject Expert Committee. Meanwhile, Zydus Cadila's needle-free COVID-19 vaccine ZyCoV-D has already received emergency use authorisation (EUA) to inoculate children in the age group of 12-18. It is expected to be administered from the first week of October.

The trials of Bharat Biotech's Covaxin COVID-19 vaccine for phases 2 & 3 for children are underway, and its result is expected in September. It is to be noted that the government has made an advance payment of Rs 1,500 crore to Biological E for 30 crore vaccines.

Biological E gets drug regulator's approval to conduct phase 2/3 trials on children

Meanwhile, Zydus Cadila's needle-free COVID-19 vaccine ZyCoV-D has already received emergency use authorisation (EUA) to inoculate children in the age group of 12-18. It is expected to be administered from the first week of October.

Also Read

AI book scam unfolds in more libraries

Kasimedu fishermen death: Why the government allowed a rough-seas venture: LoP

DMK: State autonomy's burial to appease BJP

Tamil Nadu drops tiered system for Rs 75,000 loan waiver

Ensuring quality rice in PDS, noon meal top priority: Minister Vinoth